Veracruz, Mexico

Arke Estudios Clinicos S.A. de C.V.

Dermatitis

Eczema

Atopic Dermatitis

Psoriasis

Diabetes Mellitus

Overweight

Type 2 Diabetes Mellitus

Obesity

Dulaglutide

LY2189265

Tirzepatide

LY3009104

Ixekizumab

Baricitinib

LY3298176

Lilly

condition

allSponsorName

Incyte

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The reason for this study is to see if the study drug called baricitinib works and is safe in children and teenage participants with atopic dermatitis.

A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis

Arke Estudios Clinicos S.A. de C.V. | Veracruz, Mexico

Site insights

Work at this site?

Active trials

A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis (BREEZE-AD-PEDS)

Trial sponsors